MY ACCOUNT | NEWSLETTER |

Purgo Scientific Appoints Veteran MedTech Leader as Chief Executive Officer


Purgo Scientific, a pioneering medical device company focused on bringing innovative drug delivery technologies to market, is pleased to announce the appointment of James A. Bowman as its new Chief Executive Officer.

Mr. Bowman is a seasoned healthcare executive with over 20 years’ experience leading early-stage life science companies and commercializing breakthrough medical and surgical technologies. With a background in biomedical engineering and executive training from Harvard Business School’s Owner/President Management program, Bowman brings a strong blend of technical expertise, business acumen and operational leadership to Purgo Scientific.

Throughout his career, Mr. Bowman has guided multiple MedTech companies from early-stage innovation to successful commercialization and strategic exits. Jim has raised venture capital and institutional funding, built high-performing teams and launched products across a wide range of specialties including general surgery, orthopedics, neurosurgery, cardiothoracic, gynecology, imaging and oncology.

Mr. Bowman succeeds Mike Benjamin, who has stepped down as CEO for personal health reasons. Mr. Benjamin will remain actively involved in the company as Chairman of the Board. Under his leadership, Purgo laid the foundation for its current growth, including advancing the company’s lead technology through critical development milestones, funding initiatives and assembling a strong team. The company expresses deep gratitude for Mike’s vision, dedication and continued commitment to Purgo’s mission.

“Jim is exactly the kind of leader we need at this pivotal stage of our growth,” said Mike Benjamin, Chairman of the Board. “His proven ability to bring novel surgical and drug delivery technologies to market, combined with a strong track record of operational excellence, makes him an ideal fit to lead Purgo into its next chapter.”

“I’m honored to join Purgo Scientific and build on the strong foundation Mike and the team have created,” said Mr. Bowman. “With Purgo’s unique platform technology and strong scientific underpinnings, we have the opportunity to improve patient outcomes and set a new standard of care in localized therapy.”

Purgo Scientific’s flagship innovation, currently under regulatory development, represents a new frontier in site-specific drug delivery with applications in both human and veterinary medicine. Under Mr. Bowman’s leadership, the company will accelerate product development, build strategic partnerships and position itself for long-term success in the healthcare market.

About Purgo Scientific

Purgo Scientific is a medical device company developing novel localized drug delivery technologies designed to enhance therapeutic outcomes while reducing systemic side effects. The company’s platform offers precision drug delivery across multiple clinical indications.


Source: www.purgoscientific.com

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Penn Vet Announces Interim Leadership for the Department of Clinical Sciences and Advanced Medicine, and Ryan Hospital

Like0
Dislike0

Parnell Launches nixiFLOR® - First FDA-Approved Generic Florfenicol + Flunixin Combination for BRD

Like0
Dislike0

Comparison of two host cell range variants of feline immunodeficiency virus

Like0
Dislike0

Canine babesiosis: a perspective on clinical complications, biomarkers, and treatment

Like0
Dislike0

The use of growth promoters in swine nutrition: Problems and perspectives concerning public health and swine production

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top